PathAI, a leading company in AI-powered pathology solutions, has unveiled its latest innovation in breast cancer diagnostics: the AIM-IHC Breast Panel. This advanced set of AI-assisted algorithms is designed to quantify critical breast cancer biomarkers, including HER2, ER, PR, and Ki-67, with unprecedented accuracy and consistency.
The AIM-IHC Breast Panel, now available on PathAI’s AISight® Image Management System (IMS), represents a significant advancement in the field of pathology. By providing accurate, consistent scoring directly from routine immunohistochemistry (IHC) images, this tool addresses the pressing need for standardized, reliable quantification methods to support pathologists in their critical work.
One of the key features of the AIM-IHC Breast Panel is its ability to perform automated tissue segmentation and detection of on-slide controls. The system can differentiate between areas of invasive and non-invasive cancer, providing overlays to support algorithmic scoring. This breast cancer-centric approach is specifically designed to enhance pathologist workflow, allowing for better differentiation of regions of interest and improving the accuracy of invasive cancer segmentation.
The introduction of the AIM-IHC Breast Panel marks a significant step forward in addressing the challenges associated with breast cancer biomarker quantification. Traditionally, processes such as Ki-67 scoring have been time-consuming and labor-intensive. With this new tool, pathologists can avoid spending significant time manually counting cells or relying on imprecise approximations. The panel’s automated features, including the classification of invasive cancer and generation of percentage-based results for positive cancer cells, provide pathologists with the clarity needed to produce more accurate scoring.
Andrew Beck, CEO of PathAI, emphasized the company’s commitment to advancing precision pathology, stating, ‘We are committed to advancing precision pathology with cutting-edge AI technology, empowering pathologists with the tools to make more accurate, consistent, and efficient assessments.’
The AIM-IHC Breast Panel is part of PathAI’s expanding suite of AI-powered solutions on the AISight® IMS. This platform serves as a central hub for managing pathology images, enabling seamless integration of various AI-driven tools for pathology labs. By centralizing workflows and offering a growing portfolio of applications, PathAI aims to empower pathologists and researchers to improve precision and efficiency within a unified, cloud-native platform.
The implications of this technology extend beyond individual pathology labs. By improving the accuracy and consistency of breast cancer biomarker quantification, the AIM-IHC Breast Panel has the potential to enhance the overall quality of breast cancer diagnostics and research. This could lead to more precise treatment decisions and, ultimately, better outcomes for patients.
It’s important to note that while this technology represents a significant advancement, it is currently intended for research use only and not for diagnostic procedures in the United States. In Europe, the UK, and Switzerland, the AISight Dx system has received CE-IVD marking, indicating its compliance with European regulations for in vitro diagnostic medical devices.
As PathAI continues to expand its AIM-IHC Breast Panel and other AI-powered solutions, the field of pathology is poised for a transformation. These advancements promise to streamline workflows, accelerate decision-making, and reduce time spent on manual tasks, allowing pathologists to focus more on complex cases and interpretations that require human expertise.
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is PathAI Introduces AI-Powered Breast Cancer Biomarker Quantification Tool.